Last reviewed · How we verify
NCT04372225
Predicting Risk Factors of Postoperative Hypocalcemia After Total Thyroidectomy
trial testing analysis of hypocalcemia in Hypoparathyroidism in 477 participants. Completed in 25 April 2020.
25 April 2020
Quick facts
| Lead sponsor | Aix Marseille Université |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 477 |
| Start date | 25 April 2020 |
| Primary completion | 25 April 2020 |
| Estimated completion | 25 April 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- analysis of hypocalcemia
Conditions studied
- Hypoparathyroidism — all drugs for Hypoparathyroidism →
Sponsor
Aix Marseille Université
Who can join
Eligibility, any sex, with Hypoparathyroidism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With increasing economic pressures to shorten the length of hospital stay, there has been much recent interest in studying risk factors for the development of postoperative hypocalcemia. The aim of this study was to investigate in patients undergoing total thyroidectomy whether serum calcium and/or PTH levels can predict hypoparathyroidism.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting risk factors of postoperative hypocalcemia after total thyroidectomy: is safe discharge without supplementation possible? A large cohort study.
Paladino NC, Guérin C, Graziani J, Morange I, et al · · 2021 · cited 9× · PMID 34374848 · DOI 10.1007/s00423-021-02237-2
Verify or expand the search:
- PubMed search for NCT04372225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypoparathyroidism
Currently open trials in the same condition.
- NCT06961071 — Parathyroid Allotransplant for Treatment of Hypoparathyroidism · Phase 1, PHASE2 · recruiting
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT07530705 — Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism · Phase 1, PHASE2 · recruiting
- NCT07197450 — Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism · EARLY_PHASE1 · recruiting
- NCT06645899 — Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism · recruiting
Other Aix Marseille Université trials
Trials by the same sponsor.
- NCT05915130 — An Innovative Gait Training Program in Immersive Virtual Reality for Healthy Older Adults · NA · unknown
- NCT06827106 — Dose-Quality Study in the Temporal Bone Computed Tomography in Routine Care · completed
- NCT04504643 — Comparison of Three Motor-cognitive Training Programs · NA · completed
- NCT05717881 — Impact of Poplar Propolis on Metabolic Disturbances of Insulin Resistance · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04372225 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aix Marseille Université
- Last refreshed: 1 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04372225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing